Brandon L.

CEO and President at ESI Healthcare Business Solutions

📍 United States🔄 Updated September 2026💼 14 investments📅 7 years investing🗓 Last invested Apr 2025
VC🌍 United States
14
Total investments
3
Early stage
8
Mid stage
3
Late stage
7y
Years active

Portfolio

14 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Apr 2025
We innovate and develop novel biologics for oncologic and neurologic indications that match or increase efficacy, quality of life, and overall survival over current standard of care, without the adverse effects. Existing standard cancer treatments (e.g. Carboplatin/Paclitaxel, Doxil, Elahere) sometimes reduce mortality but always with significant adverse effects, are often immune suppressive, and lead to resistance. They come at high cost (physical & financial). These realities limit who can take them and for how long. While there is high unmet need for complementary oncologic and neurologic therapies, expanding research on the cancer-killing properties of many promising biologic agents remains uncommercialized. Pebble has innovated a platform of novel biologic isolates to develop two-agent compounds (with multiple mechanisms of action and clear regulatory pathways) that outperform standard of care in multiple expressions of ovarian, lung, colorectal, breast, prostate cancer, and leukemia.
Investor and Advisor
Mar 2025
Drippy is a fun, fast-hitting weed drink made to elevate your vibe. Each can has 10mg of THC and 10mg of CBN, coming in nostalgic soda flavors, Citrus, Strawberry, and Grape. It tastes great with less sugar and natural ingredients, kicks in quick, and brings a smooth, euphoric buzz—perfect for hanging with friends or just chilling solo. No waiting, no hangover, just good vibes in a can.
Investor Through Bonaventure Equity
Jun 2024
Psilera is a scientist-owned, woman-co-founded biotechnology research company. Founded in 2019 by Jackie von Salm, PhD & Chris Witowski, PhD, Psilera is focused on early-stage drug discovery & development to provide new neurological therapeutics to the world. Psilera’s team is a dynamic collective of individuals with expertise in Synthetic Chemistry, Clinical Development, and Business Development,.
Investor and Advisor
Jun 2023
AIM7: Revolutionizing Pickleball Performance and Wellness At AIM7, our mission is to empower pickleball players to live healthy and impactful lives both on and off the court. We are the first comprehensive pickleball performance app designed to provide personalized guidance and cutting-edge tools for athletes looking to take their game to the next level. Our team of world-class sports scientists, performance coaches, and performance psychologists has developed a groundbreaking platform that seamlessly integrates with your favorite wearables, harnessing the power of data to deliver tailored recommendations for exercise, recovery, and mental fitness. Key Features: - Personalized training plans adapted to your fitness level, goals, and schedule - Dynamic warm-ups and cool-downs to prevent injuries and enhance flexibility - Customized resistance training programs for strength and power development - Expert-led video tutorials on technique, strategy, and injury prevention - In-depth performance analytics to track your progress and identify areas for improvement Whether youre a competitive player striving to dominate on the court or a passionate recreational athlete looking to stay healthy and energized, AIM7 is your ultimate companion on your pickleball journey. Experience the AIM7 difference for yourself with our free 1-month trial. Join the growing community of pickleball enthusiasts who are unlocking their potential and transforming their game with AIM7. Visit our website to learn more and start your free trial today. Together, lets revolutionize the way you approach pickleball performance and wellness. #Pickleball
Investor through Bonaventure EquityInvestor through Bonaventure Equity
Dec 2022
FloraWorks is a specialized biotech enterprise discovering rare and novel cannabinoids for commercial and therapeutic applications. We develop and patent scaled manufacturing pathways for cannabinoids with a high potential for therapeutic use while also completing the required toxicology and efficacy research to bring them to market.
mid stageManufacturing
Sensorium Therapeutics logo Investor through Bonaventure Equity
Nov 2022
Founded by world-class researchers, clinicians, and thought leaders from Massachusetts General Hospital and Harvard University, Sensorium Therapeutics is a biotechnology company leveraging cutting-edge chemistry, neuroscience, and machine learning to develop nature-derived psychoactive medicines for mental health. Inspired by the real-world human benefits of plants and fungi, Sensorium’s groundbreaking Biodynamic Discovery Platform leverages cutting-edge chemistry, neuroscience, and machine learning to reproduce, adapt, and enhance targeted molecules to elevate their utility as modern medicines that can deliver transformational benefits to patients around the world. Visit sensorium.bio to learn more.
Investor through Bonaventure Equity
Feb 2021
Novium is a pre-clinical stage biopharmaceutical company that is focused on life changing medicinal cannabis formulations coupled with innovative drug delivery systems. We specialize in developing novel, proprietary compounded therapies derived through extensive pharmacology of cannabinoids. Our therapies are focused on specific and targeted terpenoid formulations. These formulations and compounds have been created through 4 decades of research from countries all over the world. Novium’s mission is to significantly improve the lives of millions of patients through delivery of its functional plant based formulations and put them on a “Path to a Better Life”. We are on a mission to ensure that we bring the highest quality products to market that will be consistent and empower consumers to live their best lives!
Investor through Bonaventure Equity
2020
To help people understand their cannabis potency, tCheck developed the first handheld testing device for cannabis plant and infusions. We specialize in making sleek hardware with user friendly applications to enable anyone to run complex testing in a just a couple taps. With over 100,000 tests performed around the globe, tCheck is the go-to tool for at-home and on-premise cannabis testing.
Investor through Bonaventure Equity
2020
LeafWorks provides plant DNA testing for natural industries to ensure accurate labeling of products and combat fraud that is prevalent in the marketplace and has been difficult to prove until now. As one of the first companies to provide DNA testing in the cannabis industry that is from the cannabis community, LeafWorks is dedicated to ensuring that the people and organizations that built the US cannabis industry are equipped to protect their work and grow the market.
Investor through Bonaventure Equity
2020
Nalu Bio is a female-founded and led San Francisco-based biotech company committed to accelerating the potential of cannabinoids for the health of people and the planet. Nalu Bio is harnessing the power of chemistry and predictive AI modeling to solve the world’s top health and wellness challenges impacting 2 billion people globally, including pain, anxiety, sleep, and weight loss. Our proprietary pipeline of no-high, chemistry-derived cannabinoids for global CPG and therapeutics companies maintain the molecular identity of the plant while addressing the drawbacks, including safety, predictability, scalability, and sustainability. Nalu Bio offers minor cannabinoids and combinations with bioactives to provide effective, safe, and consistent products for food and beverage, health and wellness, and personal care. Additionally, our pipeline of therapeutic products mimics naturally occurring cannabinoids to develop new chemicalentities (NCEs). This approach aims to increase druggability, safety, and efficacy while potentially reducing side effects in some of the most in-demand medications on the market. Learn more at NaluBio.com and contact us at hello@nalubio.com.
Investor through Bonaventure Equity
2019
Rev Clinics is harnessing the positive power of the emerging cannabis industry to raise the standard for alternative care and generate economic opportunity across Massachusetts. At its three registered marijuana dispensaries in Cambridge and Somerville, Rev Clinics provides the highest quality medical marijuana products and the very best in-patient care and was named the best medical dispensary in the state by its peers in 2019. Its state-of-the-art cultivation facility in Fitchburg, Massachusetts is one of the largest in the state and supplies over 35 retail establishments with sought-after products and flower. Rev Clinics employs more than 230 colleagues across its manufacturing and retail operations and generated hundreds of thousands of dollars in tax revenue for Massachusetts’ communities. Through its corporate social responsibility program, Cannabis with a Conscience, Revolutionary Clinics joins with a range of partners in supporting healthy lives and vulnerable populations, advancing community revitalization efforts through philanthropy and public-private partnerships, and promoting diversity within the cannabis industry.
mid stageManufacturing
Investor
2019
Bonaventure Equity, LLC (“BVE”) is a collaboration of partners, founders, and researchers tackling healthcare’s biggest challenges. Together we work in service of patients everywhere to advance the therapeutic potential of controlled substances through science, entrepreneurship, and policy.
Investor through Bonaventure Equity
2019
RW is a unique line of herbal-based wellness products that can be incorporated into daily routines. Through our carefully chosen delivery methods of salves, tonics and vape cartridges, our products empower our clientele to harness the positive effects of herbs like cannabis in a more conscious and controlled way. With our products, even those who are trying cannabis for the first time can feel comfortable exploring its healing benefits. Through our commitment to quality, research and development, and cutting-edge cultivation and extraction processes, our intention is to be your trusted partner for balancing your mind, body and soul through the use of cannabis as an everyday wellness tool.
early stageManufacturing
Investor through Bonaventure Equity
2019
Province Brands of Canada is a beverage technology & branded products company. Our IP and technologies have applications across the alcohol industry, the cannabis industry and the functional beverage industry. We are doing something thats never been done in the history of beer. The first beers were brewed in the Zagros Mountains ~5,000 years ago. Today the beer is a $500 billion business, accounting for 1/3 of all alcohol sales. Despite countless innovations beer has always been brewed from grains (or at least some kind of starch). Province Brands of Canada has created technology to brew beers from non-starch plant material (wood, shrub or grass). Weve been using that technology to create first true alternative to alcohol: non-alcoholic beers which are brewed from cannabis and intoxicate using marijuana or its phytocannabinoids. Our technology changes the way the world thinks of beer. It allows for a further explosion in growth in the alcohol industry, where brewers can bring down costs, and brew beers with flavors never before seen. Province Brands is preparing to bring to market a diverse portfolio of premium alcohol-free fermented cannabis beverages. These products will stand apart from the infused beverages – as it is actually brewed from the cannabis plant. Beverages brewed, using this technology, are low in calories, gluten free and rich in plant phenols, plant sterols, xylooligomers and other desirable compounds. Alcohol-free variants represent a substantial disruption to the sports / nutrition functional beverage market. Our mission is to transform adult beverages. From reducing waste, to creating healthier, more sustainable, gluten-free functional brewed beverages, to creating the first ever true alternative to alcohol – premium fermented beverages brewed from cannabis that convey many of the benefits of alcohol without so many of the harms. We believe in changing the world for the better one tall, ice-cold glass at a time.
Experience · 16 entries
All (16)
Investments (14)
Founder (2)
2025
Investor
Apr 2025
We innovate and develop novel biologics for oncologic and neurologic indications that match or increase efficacy, quality of life, and overall survival over current standard of care, without the adverse effects. Existing standard cancer treatments (e.g. Carboplatin/Paclitaxel, Doxil, Elahere) sometimes reduce mortality but always with significant adverse effects, are often immune suppressive, and lead to resistance. They come at high cost (physical & financial). These realities limit who can take them and for how long. While there is high unmet need for complementary oncologic and neurologic therapies, expanding research on the cancer-killing properties of many promising biologic agents remains uncommercialized. Pebble has innovated a platform of novel biologic isolates to develop two-agent compounds (with multiple mechanisms of action and clear regulatory pathways) that outperform standard of care in multiple expressions of ovarian, lung, colorectal, breast, prostate cancer, and leukemia.
Investor and Advisor
Mar 2025
Drippy is a fun, fast-hitting weed drink made to elevate your vibe. Each can has 10mg of THC and 10mg of CBN, coming in nostalgic soda flavors, Citrus, Strawberry, and Grape. It tastes great with less sugar and natural ingredients, kicks in quick, and brings a smooth, euphoric buzz—perfect for hanging with friends or just chilling solo. No waiting, no hangover, just good vibes in a can.
2024
Investor Through Bonaventure Equity
Jun 2024
Psilera is a scientist-owned, woman-co-founded biotechnology research company. Founded in 2019 by Jackie von Salm, PhD & Chris Witowski, PhD, Psilera is focused on early-stage drug discovery & development to provide new neurological therapeutics to the world. Psilera’s team is a dynamic collective of individuals with expertise in Synthetic Chemistry, Clinical Development, and Business Development,.
2023
Investor and Advisor
Jun 2023
AIM7: Revolutionizing Pickleball Performance and Wellness At AIM7, our mission is to empower pickleball players to live healthy and impactful lives both on and off the court. We are the first comprehensive pickleball performance app designed to provide personalized guidance and cutting-edge tools for athletes looking to take their game to the next level. Our team of world-class sports scientists, performance coaches, and performance psychologists has developed a groundbreaking platform that seamlessly integrates with your favorite wearables, harnessing the power of data to deliver tailored recommendations for exercise, recovery, and mental fitness. Key Features: - Personalized training plans adapted to your fitness level, goals, and schedule - Dynamic warm-ups and cool-downs to prevent injuries and enhance flexibility - Customized resistance training programs for strength and power development - Expert-led video tutorials on technique, strategy, and injury prevention - In-depth performance analytics to track your progress and identify areas for improvement Whether youre a competitive player striving to dominate on the court or a passionate recreational athlete looking to stay healthy and energized, AIM7 is your ultimate companion on your pickleball journey. Experience the AIM7 difference for yourself with our free 1-month trial. Join the growing community of pickleball enthusiasts who are unlocking their potential and transforming their game with AIM7. Visit our website to learn more and start your free trial today. Together, lets revolutionize the way you approach pickleball performance and wellness. #Pickleball
2022
Investor through Bonaventure EquityInvestor through Bonaventure Equity
Dec 2022
FloraWorks is a specialized biotech enterprise discovering rare and novel cannabinoids for commercial and therapeutic applications. We develop and patent scaled manufacturing pathways for cannabinoids with a high potential for therapeutic use while also completing the required toxicology and efficacy research to bring them to market.
mid stageManufacturing
Show all 16 entries ↓
Investment activity
2019–2025 · 14 investments
20194202032021120222202312024120252
Recent (last 2 years)Earlier